A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up

Surface Ophthalmics, Inc.28 sites in 1 country139 target enrollmentJanuary 7, 2021

ConditionsDry Eye Disease

Interventions0.02% Betamethasone Sodium Phosphate 0.04% Betamethasone Sodium Phosphate Placebo

Drugs0.02% Betamethasone Sodium Phosphate 0.04% Betamethasone Sodium Phosphate Placebo

Overview

Phase: Phase 2
Intervention: 0.02% Betamethasone Sodium Phosphate
Conditions: Dry Eye Disease
Sponsor: Surface Ophthalmics, Inc.
Enrollment: 139
Locations: 28
Primary Endpoint: University of North Carolina Dry Eye Management Scale (UNC DEMS) Responder Analysis
Status: Completed
Last Updated: 11 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.

The purpose of this research study is to see how well SURF-200 works and what side effects there are, and to compare it with vehicle (placebo). The study will involve about 120 study participants at multiple research sites in the United States.

Registry

clinicaltrials.gov

Start Date

January 7, 2021

End Date

October 12, 2022

Last Updated

11 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Surface Ophthalmics, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects 18 years of age and older who have a diagnosis of dry eye disease and experiencing an episodic flare up. Criteria for the diagnosis must include the following:
•UNC DEMS score of greater than or equal to 5 but less than or equal to 9
•Conjunctival hyperemia score of greater than or equal to 2 in the study eye when using the conjunctival hyperemia reference photos
•Schirmer's Tear Test score (with anesthesia) greater than 1 mm but less than or equal to12 mm in the study eye
•Subjects must be able to understand and sign the Informed Consent Form (ICF).
•Female subjects of childbearing potential must agree to and submit a negative urine pregnancy test before any study-specific procedures are performed. The subjects must be using and continue to use a suitable method of contraception for the duration of the study: spermicide with barrier, oral contraceptive, transdermal contraceptive, injectable or implantable contraceptive, intrauterine device (IUD), abstinence or surgical sterilization of a partner. If a subject is not of childbearing potential (e.g., has been postmenopausal for at least 12 months or is premenarchal, or has undergone a hysterectomy, bilateral oophorectomy or a bilateral tubal ligation), a urine pregnancy test and use of a suitable method of contraception for the duration of the study will not be required.
•Subjects must have a best-corrected visual acuity (BCVA) of at least +1.0 log of the minimum angle of resolution (logMAR) (Snellen equivalent of 20/200) in the non-study eye (fellow eye).
•Subjects must have an intraocular pressure (IOP) of \>8 mmHg and ≤22 mmHg in the study eye.
•Subjects who are on Restasis, Xiidra or other cyclosporine ophthalmic eye drops must be on a stable dose for at least 4 months prior to Screening Visit 1 (Day -14 to Day 0) and remain compliant with the use of these medications throughout the duration of this study.
•Subjects who are on artificial tears, oral antihistamines, beta blockers and diuretics must be on a stable dose for at least 1 month prior to Screening Visit 1 (Day -14 to Day 0) and remain compliant with the use of these medications throughout the duration of this study.

Exclusion Criteria

•Females who are pregnant or nursing or planning to become pregnant during the study. Females of childbearing potential (not surgically sterilized or postmenopausal) may not participate in the study if they do not agree to use adequate birth control methods for the duration of the study.
•Use of contact lenses in either eye during the study. Contact lens wear must have been discontinued at least 2 weeks prior to Baseline/Randomization Visit 2 (Day 1).
•Use of corticosteroids or nonsteroidal anti-inflammatory agents (NSAID) (except oral doses of aspirin at 81 mg/day or lower) within 2 weeks of the initiation of study drug at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the study.
•Inhaled, ingested, sublingual, transdermal or topical products containing marijuana, tetrahydrocannabinol (THC) or cannabidiol (CBD) within 7 days of the first dose of study drug at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the study.
•Presence or history of treatment with systemic immunosuppressive or chemotherapeutic agents.
•History of high IOP response to steroids.
•Participated in an ophthalmic investigational product clinical trial within 30 days of Screening Visit 1 (Day -14 to Day 0).
•Active collagen vascular disorder or autoimmune disease.
•A condition or a situation, which in the investigator's opinion may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
•Known hypersensitivity to any component of the study drug or procedural medications.

Arms & Interventions

SURF-200 (0.02% betamethasone sodium phosphate in vehicle)

One drop twice daily (BID) in the study eye for 14 days.

Intervention: 0.02% Betamethasone Sodium Phosphate

SURF-200 (0.04% betamethasone sodium phosphate in vehicle)

One drop BID in the study eye for 14 days.

Intervention: 0.04% Betamethasone Sodium Phosphate

Vehicle

One drop BID in the study eye for 14 days.

Intervention: Placebo

Outcomes

Primary Outcomes

University of North Carolina Dry Eye Management Scale (UNC DEMS) Responder Analysis

Time Frame: Baseline and Day 8

The UNC DEMS scale is a participant-specific 10-point scale with a minimum score of 1 (\[1-2\] My symptoms are not a problem. My dry eye does not affect my daily life at all) and a maximum score of 10 (\[9-10\] my symptoms are severe and I need immediate medical care. My dry eye greatly affects my daily life). Participants with a minimum reduction of ≥1 point in UNC DEMS score from baseline were defined as responders, and response rates were summarized by treatment group.

Secondary Outcomes

University of North Carolina Dry Eye Management Scale (UNC DEMS) Responder Analysis(Baseline and Day 15)
Conjunctival Hyperemia Responder Analysis(Baseline and Day 8)